Obatoclax Rescues FUS-ALS Phenotypes in iPSC-Derived Neurons by Inducing Autophagy

Author:

Castillo Bautista Cristina Marisol1,Eismann Kristin2,Gentzel Marc2ORCID,Pelucchi Silvia34,Mertens Jerome356ORCID,Walters Hannah E.1,Yun Maximina H.178ORCID,Sterneckert Jared19ORCID

Affiliation:

1. Center for Regenerative Therapies TU Dresden (CRTD), Technische Universität Dresden, 01307 Dresden, Germany

2. Core Facility Mass Spectrometry & Proteomics, Center for Molecular and Cellular Bioengineering, Technische Universität Dresden, 01307 Dresden, Germany

3. Department of Neurosciences, University of California San Diego, La Jolla, CA 92161, USA

4. Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, 20133 Milan, Italy

5. Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA

6. Institute for Molecular Biology, University of Innsbruck, A-6020 Innsbruck, Austria

7. Max Planck Institute for Molecular Cell Biology and Genetics, 01307 Dresden, Germany

8. Cluster of Excellence Physics of Life, Technische Universität Dresden, 01307 Dresden, Germany

9. Medical Faculty Carl Gustav Carus of TU Dresden, 01307 Dresden, Germany

Abstract

Aging is associated with the disruption of protein homeostasis and causally contributes to multiple diseases, including amyotrophic lateral sclerosis (ALS). One strategy for restoring protein homeostasis and protecting neurons against age-dependent diseases such as ALS is to de-repress autophagy. BECN1 is a master regulator of autophagy; however, is repressed by BCL2 via a BH3 domain-mediated interaction. We used an induced pluripotent stem cell model of ALS caused by mutant FUS to identify a small molecule BH3 mimetic that disrupts the BECN1-BCL2 interaction. We identified obatoclax as a brain-penetrant drug candidate that rescued neurons at nanomolar concentrations by reducing cytoplasmic FUS levels, restoring protein homeostasis, and reducing degeneration. Proteomics data suggest that obatoclax protects neurons via multiple mechanisms. Thus, obatoclax is a candidate for repurposing as a possible ALS therapeutic and, potentially, for other age-associated disorders linked to defects in protein homeostasis.

Funder

DFG Research Center

Cluster of Excellence

DFG

German Federal Ministry of Education and Research (BMBF) program ‘Unternehmen Region’

German Research Foundation

European Regional Development Fund

BrightFocus Foundation

European Union

National Institute on Aging

Alexander von Humboldt postdoctoral research fellowship

TU Dresden Graduate Academy ‘Postdoc Starter Kit’ grant

Deutsche Forschungsgemeinschaft grants

TUD-CRTD core funds

Publisher

MDPI AG

Subject

General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3